Leveraging lessons learned from the COVID-19 pandemic for HIV.

Autor: Calder T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., Tong T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., Hu DJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., Kim JH; International Vaccine Institute, Seoul, Republic of Korea., Kotloff KL; University of Maryland School of Medicine, Baltimore, MD USA., Koup RA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., McElrath MJ; Fred Hutchinson Cancer Research Center, Seattle, WA USA., Read SW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., Robb ML; Walter Reed Army Institute of Research, Silver Spring, MD USA., Renzullo PO; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA., D'Souza MP; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland USA.
Jazyk: angličtina
Zdroj: Communications medicine [Commun Med (Lond)] 2022 Aug 29; Vol. 2, pp. 110. Date of Electronic Publication: 2022 Aug 29 (Print Publication: 2022).
DOI: 10.1038/s43856-022-00175-8
Abstrakt: The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.
Competing Interests: Competing interestsThe authors declare no competing interests.
(© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022.)
Databáze: MEDLINE
Externí odkaz: